Study to Evaluate Safety, Tolerability and Pharmacodynamics of KP104 in Participants With Thrombotic Microangiopathy Secondary to Systemic Lupus Erythematosus

NCT05504187 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Systemic Lupus Erythematosus

Interventions

DRUG: KP104

Sponsor

Kira Pharmacenticals (US), LLC.